Table 2.
Univariate and multivariate Cox survival analyes of OS in PC patients.
| Characteristics | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Age (Reference: < 68) | ||||
| 68–79 | 1.637 (1.415–1.894) | < 0.001 | 1.458 (1.253–1.697) | < 0.001 |
| > 79 | 2.620 (2.222–3.089) | < 0.001 | 1.917 (1.602–2.295) | < 0.001 |
| Sex (Reference: Female) | ||||
| Male | 1.059 (0.924–1.215) | 0.408 | 1.125 (0.977–1.295) | 0.104 |
| Race (Reference: Black) | ||||
| White | 0.794 (0.655–0.963) | 0.019 | 0.780 (0.639–0.954) | 0.153 |
| Other | 0.814 (0.645–1.028) | 0.083 | 0.768 (0.605–0.975) | 0.030 |
| Tumor size (Reference: < 2.6) | ||||
| 2.6–3.5 | 2.041 (1.700–2.450) | < 0.001 | 1.213 (0.989–1.487) | 0.063 |
| > 3.5 | 2.215 (1.874–2.617) | < 0.001 | 1.372 (1.129–1.668) | 0.001 |
| Grade (Reference: Well differentiated) | ||||
| Moderately differentiated | 2.842 (2.103–3.842) | < 0.001 | 1.958 (1.427–2.687) | < 0.001 |
| Poorly differentiated | 4.278 (3.132–5.844) | < 0.001 | 2.472 (1.780–3.434) | < 0.001 |
| Undifferentiated | 3.671 (1.582–8.518) | 0.002 | 1.969 (0.825–4.699) | 0.127 |
| Unknown | 6.081 (4.615–8.013) | < 0.001 | 1.87 5(1.380–2.549) | < 0.001 |
| Radiotherapy (Reference: None/Unknown) | ||||
| Yes | 0.797 (0.670–0.948) | 0.010 | 0.991 (0.820–1.198) | 0.924 |
| Chemotherapy (Reference: None/Unknown) | ||||
| Yes | 0.960 (0.843–1.093) | 0.536 | 0.480 (0.429–0.582) | < 0.001 |
| Surgery (Reference: None/Unknown) | ||||
| Yes | 0.256 (0.218–0.300) | < 0.001 | 0.340 (0.268–0.431) | < 0.001 |
| AJCC T status (Reference: T1) | ||||
| T2 | 3.890 (2.811–5.385) | < 0.001 | 1.394 (0.963–2.018) | 0.079 |
| T3 | 3.845 (2.802–5.277) | < 0.001 | 1.449 (1.000–2.100) | 0.049 |
| T4 | 4.907 (3.523–6.835) | < 0.001 | 1.225 (0.823–1.823) | 0.318 |
| Unknown | 8.497 (5.693–12.683) | < 0.001 | 1.996 (1.282–3.106) | 0.002 |
| AJCC N status (Reference: N0) | ||||
| N1 | 1.124 (0.985–1.281) | 0.082 | 1.192 (1.029–1.382) | 0.019 |
| Unknown | 2.834 (2.155–3.727) | < 0.001 | 1.748 (1.315–2.323) | < 0.001 |
| AJCC M status (Reference: M0) | ||||
| M1 | 2.401 (2.110–2.732) | < 0.001 | 1.826 (1.557–2.142) | < 0.001 |
| Primary site (Reference: Head of pancreas) | ||||
| Body of pancreas | 0.911 (0.762–1.089) | 0.307 | 0.844 (0.698–1.021) | 0.081 |
| Tail of pancreas | 0.744 (0.607–0.913) | 0.005 | 0.789 (0.630–0.987) | 0.038 |
| Pancreatic duct | 1.518 (0.679–3.394) | 0.310 | 1.270 (0.562–2.872) | 0.566 |
| Other specified parts of pancreas | 0.860 (0.576–1.284) | 0.461 | 0.840 (0.559–1.262) | 0.401 |
| Overlapping lesion of pancreas | 1.081 (0.859–1.361) | 0.506 | 1.007 (0.791–1.283) | 0.953 |
| Pancreas, NOS | 1.236 (0.927–1.648) | 0.148 | 1.199 (0.887–1.620) | 0.237 |
| Histological subtype (Reference: Adenocarcinoma) | ||||
| Infiltrating duct carcinoma | 0.510 (0.418–0.622) | < 0.001 | 1.0245 (0.815–1.288) | 0.836 |
| Neuroendocrine carcinoma | 0.124 (0.086–0.180) | < 0.001 | 0.153 (0.103–0.227) | < 0.001 |
| Other | 0.436 (0.351–0.543) | < 0.001 | 0.552 (0.430–0.708) | < 0.001 |
| Prior thyroid cancer history (Reference: without) | ||||
| With | 0.876 (0.702–1.093) | 0.240 | 0.824 (0.652–1.041) | 0.104 |
OS overall survival, AJCC American Joint Commission on Cancer(7th), SEER the surveillance, epidemiology, and end results, HR hazard ratio, CI confidence interval.